Compare Norfolk Southern Corporation (NSC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novavax Inc — how do they compare? Norfolk Southern Corporation trades at $333 (market cap $75.23B), while Novavax Inc trades at $8.12 (market cap $1.30B). The key difference: Norfolk Southern Corporation is far larger — about 57.9× Novavax Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NSC | NVAX | |
|---|---|---|
Market Cap | $75.23B | $1.30B |
Sector | Technology | Health |
52-Week High | $340.16 | $11.19 |
52-Week Low | $272.35 | $6.22 |
Enterprise Value | $90.99B | $800.50M |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.97, down 1.53% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Key developments include the pending Q2 2026 earnings report on July 23, 2026, and ongoing regulatory review of the proposed merger with Union Pacific, which dominates recent news coverage.
The investment outlook is cautiously optimistic, supported by earnings momentum and a consensus price target of $344.40 offering modest upside. Risks include potential regulatory hurdles for the merger, declining revenue projections for 2026, and elevated valuation multiples. The stock's current price near resistance levels suggests near-term volatility around earnings could present entry opportunities for long-term investors.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
